Seeking Alpha

Newlink Genetics (NLNK +4.3%) gains today after European regulators grant orphan drug status for...

Newlink Genetics (NLNK +4.3%) gains today after European regulators grant orphan drug status for Algenpantucel-L, the company's off-the-shelf product candidate for treatment of pancreatic cancer. The drug is currently is in Phase III testing in the U.S.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector